F9: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of F9. The page also collects GeneMedi's different modalities and formats products for F9 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the F9 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Sep 2015]

Pre-made F9-specific INN-index biosimilar (antibody&conjugates)-albutrepenonacog alfa, nonacog gamma, dalcinonacog alfa, Emicizumab, eftrenonacog alfa

Anti-F9 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.	Products Name (INN Index)	INN Name	Previous Name	Target	Format	Order
GMP-Bios-INN-726	Pre-Made Albutrepenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8	albutrepenonacog alfa		F9	Fusion Protein
GMP-Bios-INN-929	Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8	nonacog gamma		F9	Recombinant Protein
GMP-Bios-INN-792	Pre-Made Dalcinonacog Alfa Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8	dalcinonacog alfa		F9	Recombinant Protein
GMP-Bios-ab-177	Pre-Made Emicizumab biosimilar, Bispecific mAb, Anti-F9;F10 Antibody: Anti-FIX/HEMB/P19/PTC/THPH8;FX/FXA therapeutic antibody	Emicizumab		F9;F10	Bispecific mAb
GMP-Bios-INN-830	Pre-Made Eftrenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8	eftrenonacog alfa		F9	Fusion Protein

Pre-made anti-F9 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-F9 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-F9 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.	Antibody Name	Format	Classified by tag	Order
GM-Tg-hg-T83369-Ab	Anti-F9 monoclonal antibody	mab	Biofunctional antibody, Therapeutics Target antibody